Spyre Therapeutics Inc.

NASDAQ: SYRE · Real-Time Price · USD
16.95
0.09 (0.53%)
At close: Aug 15, 2025, 3:45 PM

Spyre Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a 1.04M 1.04M 1.73M 1.93M 1.05M 1.23M 1.17M 2.33M 5.8M 7.03M 20.1M 18.74M 15.1M 13.7M n/a
Cost of Revenue
n/a n/a n/a 964K 964K 1.38M 1.93M 1.45M 1.96M 2.02M 1.96M 1.98M 1.47M 999K 502K n/a n/a n/a
Gross Profit
n/a n/a n/a 78K 78K 350K n/a -400K -728K -850K 365K 3.83M 5.56M 19.1M 18.24M 15.1M 13.7M n/a
Operating Income
-222.15M -214.36M -208.57M -193.23M -156.17M -271.27M -242.3M -215.55M -215.97M -79.15M -84.78M -86.06M -87.6M -71.88M -65.65M -67.98M -65.81M -80.67M
Interest Income
23.33M 23.37M 21.31M 19.66M 15.73M 10.16M 6.15M 2.43M 1.47M 1.22M 837K 461K 209K 124K 111K 121K 173K 315K
Pretax Income
-206.81M -208.93M -207.97M -214.85M -185.95M -364.18M -338.82M -294.42M -272.76M -78M -83.98M -85.62M -87.45M -71.88M -65.66M -67.95M -65.7M -80.38M
Net Income
-206.81M -208.93M -208.02M -214.9M -185.98M -364.23M -338.79M -294.43M -272.56M -77.8M -83.81M -85.44M -87.51M -72.02M -65.8M -68.07M -65.8M -80.38M
Selling & General & Admin
45.15M 44.87M 45.78M 49.08M 47.01M 47.56M 39.95M 30.46M 28.33M 23.47M 26.57M 28.78M 28.64M 27.75M 25.78M 26M 25.36M 23.74M
Research & Development
176.99M 169.49M 162.79M 145.99M 125.91M 110.66M 89.5M 70.07M 57.39M 55.38M 58.58M 61.11M 63.99M 62.19M 57.07M 56.04M 53.64M 56.93M
Other Expenses
n/a n/a n/a -21.39M -21.39M -21.4M -21.47M -80K -80K -72K n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
222.15M 214.36M 208.57M 195.07M 172.92M 158.22M 129.45M 100.54M 85.72M 78.84M 85.15M 89.89M 92.63M 89.95M 82.85M 82.04M 79M 80.67M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
168.58M 160.79M 208.57M 195.07M 172.92M 158.22M 129.45M 101.03M 86.71M 80.31M 87.11M 91.87M 94.63M 91.98M 84.39M 83.08M 79.51M 80.67M
Income Tax Expense
34K 34K -13K -14K -29K -22K -26K 12K -200K -198K -162K -177K 58K 141K 141K 118K 92K n/a
Shares Outstanding (Basic)
60.7M 60.27M 47.03M 50.89M 45.32M 36.51M 6.9M 4.29M 3.82M 3.77M 2.61M 3.77M 3.29M 2.64M 1.97M 2.63M 2.63M 2.62M
Shares Outstanding (Diluted)
60.7M 60.27M 47.03M 50.89M 45.32M 36.51M 6.9M 4.29M 3.82M 3.77M 2.61M 3.77M 3.29M 2.64M 1.97M 2.63M 2.63M 2.62M
EPS (Basic)
-2.24 -2.5 -3.57 -14.71 -22.69 -78.62 -82.31 -78.22 -73.72 -23.72 -28.09 -31.25 -34.13 -29.94 -27.62 -27.08 -26.6 -34.11
EPS (Diluted)
-2.24 -2.5 -3.57 -14.71 -22.69 -78.62 -82.31 -78.22 -73.72 -23.72 -28.09 -31.25 -34.13 -29.94 -27.62 -27.08 -26.6 -34.11
EBITDA
-206.93M -214.36M -208.57M -195.07M -172.92M -157.12M -127.6M -98.52M -83.53M -77.13M -82.82M -84.08M -85.6M -69.88M -63.79M -66.26M -64.36M -79.47M
EBIT
-148.4M -155.83M -203.61M -195.07M -172.92M -157.53M -128.56M -99.97M -85.48M -79.15M -84.78M -86.06M -87.6M -71.88M -65.65M -67.98M -65.81M -80.67M
Depreciation & Amortization
n/a n/a 43.28K -176.72K -216.31K 199.69K 704.41K 1.41M 1.96M 2.02M 1.96M 1.98M 2M 2.04M 1.89M 1.76M 1.48M 1.2M